Cytokinetics, Incorporated
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| KK3A.F | EWTX | SLDB | SRRK | BBIO | BMRN | |
|---|---|---|---|---|---|---|
| Market cap | 7.77B | 4.08B | 699.11M | 5.61B | 15.17B | 11.06B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -16.4 | -20.1 | -3.8 | -18.6 | -225.0 | 9.0 |
| Price/book | -11.7 | 7.6 | 2.9 | 22.1 | -5.9 | 1.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +5.48% | +119.60% | +54.69% | +60.03% | +24.17% | +10.20% |
| Today | +2.08% | −0.40% | +3.82% | +4.80% | +5.21% | +2.64% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All KK3A.F news ›Cytokinetics (CYTK) Expected to Post Earnings on Wednesday
Posted by Tristan Rich on Oct 28th, 2026 CYTK stock opened at $61.52 on Wednesday. The firm has a 50 day moving average of $68.37 and a 200-day moving average of $70.08. Cytokinetics has a 12-month low of $58.05 and a 12-month high of…
Analyzing Inhibrx Biosciences (NASDAQ:INBX) and Cytokinetics (NASDAQ:CYTK)
Posted by Mitch Edgeman on Oct 25th, 2026 Cytokinetics (NASDAQ:CYTK – Get Free Report) and Inhibrx Biosciences (NASDAQ:INBX – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two…
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) vs. Cytokinetics (NASDAQ:CYTK) Head-To-Head Review
Posted by Defense World Staff on Oct 25th, 2026 Kiniksa Pharmaceuticals International (NASDAQ:KNSA – Get Free Report) and Cytokinetics (NASDAQ:CYTK – Get Free Report) are both mid-cap healthcare companies, but which is the superior…
Insider Selling: Cytokinetics (NASDAQ:CYTK) EVP Sells $224,035.00 in Stock
Posted by Danessa Lincoln on Oct 23rd, 2026 Fady Ibraham Malik also recently made the following trade(s): Shares of CYTK opened at $62.33 on Friday. Cytokinetics, Incorporated has a 1 year low of $54.30 and a 1 year high of $88.31. The…
Cytokinetics director Wysenski awarded 97 shares
Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million Financing Bloom Energy Reports Record Third Quarter 2026 Financial Results and Raises Full Year 2026 Guidance WD Reports Fiscal First Quarter…
Cytokinetics director James M. Daly awarded 195 shares
Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million Financing Bloom Energy Reports Record Third Quarter 2026 Financial Results and Raises Full Year 2026 Guidance WD Reports Fiscal First Quarter…
BridgeBio, Madrigal, Cytokinetics Trade Lower Ahead of Q3 Results Amid Lack of Near-Term Catalysts, BofA Says
BridgeBio Pharma , Madrigal Pharmaceuticals and Cytokinetics traded meaningfully lower in recent weeks as investors question the merits of holding positions in the US biotech stocks amid a lack... Biotechnology & Medical Research…
William Blair Initiates Coverage on Cytokinetics With Outperform Rating
Cytokinetics has an average rating of buy and mean price target of $109.95, according to analysts polled by FactSet. ... Biotechnology & Medical Research William Blair Initiates Coverage on Cytokinetics With Outperform Rating Published on…
More from 1 other outlet
BofA Securities Adjusts Price Target on Cytokinetics to $81 From $85, Maintains Neutral Rating
Cytokinetics has an average rating of buy and mean price target of $109.20, according to analysts polled by FactSet. ... Biotechnology & Medical Research BofA Securities Adjusts Price Target on Cytokinetics to $81 From $85, Maintains…
More from 1 other outlet
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on October 15, 202... SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated…
From the 4Search news index, newest first.